Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale

Michael S. KostapanosDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK; ;Lipid Clinic, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Correspondence[email protected]

Paul J. CacciottoloDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK;

Annette HubschDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK;

Holly PaveyCardiovascular Trials Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

http://orcid.org/0000-0001-5014-5118

James HurlockCardiovascular Trials Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Kaisa Maki-PetajaDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK;

Ian B. WilkinsonDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK; ;Cardiovascular Trials Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Joseph CheriyanDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK; ;Cardiovascular Trials Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

show all

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date